FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bradway Robert A						2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]									ationship all app Direc	,	ng Pers	son(s) to Is	
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 03/19/2021									X	belov	,	Other (specify below) O and President		
(Street) THOUS	AND CA		01320-1	1799	4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Indi	·				
(City)	(50		able I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)  Common Stock  03/19/20					ZA. Deemed Execution Date, if any (Month/Day/Year)			3. Transa Code ( 8) Code	ction	4. Securities Disposed Of 5)  Amount 21,190	s Acqui	red (A) o	r und	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			Transaction Code (Instr. 8)  Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5		rities ired r osed )	6. Date Expira (Month	tion Da h/Day/\		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amoun or Numbe of Title Shares		t r		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		LO. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5.019 RSUs which vest on 5/1/2021; 9.439 RSUs which vest in installments of 4.649 on 4/27/2021 and 4.790 on 4/27/2022; 15.791 RSUs which vest in two installments of 5.211 on 5/3/2021 and 5/3/2022 and one installment of 5.369 on 5/3/2023; and 12.184 RSUs which vest in installments of 4.020 on 5/05/2022, 4.021 on 5/5/2023 and 4.143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 2. These shares include 2,728 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

/s/ Robert A. Bradway

03/19/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.